Management of Cushing Disease After Transsphenoidal Surgery
The clinical approach to management of Cushing disease is often complex and education on a clear approach is paramount.
Cushing Syndrome
CUSHING SYNDROME
Featured Article
Latest News
Novel Therapy for Cushing Disease Receives FDA Approval
The Food and Drug Administration (FDA) has approved Isturisa® (osilodrostat; Recordati) for the treatment of adults with Cushing disease for whom pituitary surgery is not an option or has not been curative.
No Clear Distinguishing Factors for Primary Aldosteronism Plus Subclinical Cushing Syndrome
No reference criteria can definitively distinguish patients with primary aldosteronism and subclinical Cushing syndrome from those with these conditions alone.
Levoketoconazole Effectively Treats Endogenous Cushing Syndrome in Phase 3 Trial
According to results of the phase 3 SONICS trial, levoketoconazole is a safe and effective treatment option for patients with Cushing syndrome.
Sex Affects Clinical Presentation of ACTH-Dependent Cushing Syndrome
Researchers examined sex differences in clinical presentation and patient outcomes in ACTH-dependent Cushing syndrome.
Signs and Symptoms of Adrenal Medullary Hyperplasia vs Pheochromocytoma
Patients with AMH without pheochromocytoma had milder symptoms compared with patients with pheochromocytoma only.
Mifepristone an Effective Alternative to Surgery for Patients With Bilateral Macronodular Adrenal Hyperplasia
Mifepristone may be an effective alternative to adrenalectomy in patients with hypercortisolism caused by primary bilateral macronodular adrenal hyperplasia.
Transsphenoidal Surgery Recommended for Cushing Disease With Inconclusive or Normal MRI
In the absence of clear evidence of a pituitary adenoma on imaging, there is some controversy regarding the best treatment for Cushing disease.
High Prevalence of Diabetes in Patients With Primary Aldosteronism
Prevalence of diabetes is higher in patients with primary aldosteronism and was found to be related to suspected subclinical hypercortisolism.
New Data for Potential Cushing Syndrome Treatment Levoketoconazole Announced
Researchers reported that mean urinary-free cortisol (mUFC) normalization with Recorlev was similar in patients with and without diabetes.
Elevated Plasma Agouti-Related Protein May Be a Marker for Cushing Disease
Plasma levels of the orexigenic neuropeptide agouti-related protein (AgRP) are elevated in Cushing disease, and it may be a marker of hypothalamic AgRP.
Positive Results for Recorlev in Phase 3 Cushing Syndrome Trial
Results from this single-arm, open-label study found that 30% of patients achieved normalization of mean urinary free cortisol (UFC) after 6 months of maintenance treatment with levoketoconazole, without a dose increase (P<.25).
Want to read more?
Please login or register first to view this content.
